Founded in 2020, Anviron is a University Co-founded team of oncologists and biochemest specializing in the glycobiome, an emerging area of study that relates protein synthesis & development to human diseases such as cancer.
We are a team of entrepreneurial and passionate scientists, doctors, and clinicians that are dedicated to bringing our promising therapies to light.
IN THE NEWS
Jul 25, 2022 - Physician, researcher and pioneer oncologist Jack Singer M.D. joins Anviron Board of Advisors. Dr. Singer is former Chief of Medical Oncology with the Seattle VA hospital where he piloted what would become the marrow transplante program of the entire VA system, an important procedure in restoring patient bone marrow after cytotoxic chemotherapy. As founder and Chief Science Officer of Cell Therapeutics, Dr. Singer was responsible for drug discovery including several IND, and NDA applications for oncology candidates. Dr. Singer is a Professor of Oncology at Washington State University, College of Medicine.
Oct 12, 2021 - The United States Food and Drug Administration (FDA) has granted “Orphan Drug Designation” to our drug candidate ANV221 for the treatment of pancreatic cancers. This important milestone confers the benefit of seven (7) years of market exclusivity in the United States and validates the team’s hard work toward developing a promising therapy for this difficult to treat disease.
Mar 18, 2021 - UTRF, UTHSC, and Anviron Partner to Commercialize Novel Treatment for Pancreatic Cancer - The University of Tennessee Research Foundation, the University of Tennessee Health Science Center and biotech therapeutics startup Anviron recently announced a partnership to commercialize a novel product candidate with promising efficacy against pancreatic cancer tumors.
Dec 28, 2020 - University of Tennessee Research Foundation & Anviron announce agreement to an exclusive, world-wide license to commercialize a novel low toxicity DPAGT-1 inhibitor with demonstrated in vivo efficacy against pancreatic cancer tumors.